Polaryx Therapeutics, Inc. Common Stock

Polaryx Therapeutics Receives U.S. FDA Fast Track Designations for All Four Indications to be Evaluated in the SOTERIA Basket Trial

Polaryx Therapeutics Recognized with Pinnacle Award for Excellence in Pediatric Care

Polaryx Therapeutics To Participate In The 25th Annual Needham Virtual Healthcare Conference

Polaryx Therapeutics Receives FDA Fast Track Designation for PLX‑200 for Late‑Infantile Neuronal Ceroid Lipofuscinosis (CLN2 Disease)

Polaryx Therapeutics Deepens Engagement with the Krabbe Disease Community Through Scientific and Patient Advocacy Events